CHGCF (Chugai Pharmaceutical Co) 3-Year Book Growth Rate : 18.30% (As of Jun. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co 3-Year Book Growth Rate?

Chugai Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2024 was $6.74.

During the past 12 months, Chugai Pharmaceutical Co's average Book Value per Share Growth Rate was 15.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was 18.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was 17.20% per year. During the past 10 years, the average Book Value per Share Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Chugai Pharmaceutical Co was 18.60% per year. The lowest was 2.30% per year. And the median was 6.60% per year.

Competitive Comparison of Chugai Pharmaceutical Co's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's 3-Year Book Growth Rate falls into.

Chugai Pharmaceutical Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Chugai Pharmaceutical Co (OTCPK:CHGCF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Chugai Pharmaceutical Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

CHGCY:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.